Search
Now showing items 1-6 of 6
Core outcomes in gestational diabetes for treatment trials: The Gestational Metabolic Group treatment set
(
John Wiley and Sons Inc
, 2021 , Article)
Aims
With the rising number of outcomes being reported following gestational diabetes (GDM), the outcomes in existing studies vary widely making it challenging to compare and contrast the effectiveness of different ...
Mortality prediction utilizing blood biomarkers to predict the severity of COVID-19 using machine learning technique
(
MDPI
, 2021 , Article)
Healthcare researchers have been working on mortality prediction for COVID-19 patients with differing levels of severity. A rapid and reliable clinical evaluation of disease intensity will assist in the allocation and ...
Generation of gene edited hiPSC from familial Alzheimer's disease patient carrying N141I missense mutation in presenilin 2
(
Elsevier B.V.
, 2021 , Article)
Alzheimer's disease (AD) is the major cause of dementia worldwide. Early-onset familial AD accounts for about 0.5% of all AD and is caused by single major gene mutations and autosomal dominant inheritance. An N141I missense ...
COVID-19 infection localization and severity grading from chest X-ray images
(
Elsevier Ltd
, 2021 , Article)
The immense spread of coronavirus disease 2019 (COVID-19) has left healthcare systems incapable to diagnose and test patients at the required rate. Given the effects of COVID-19 on pulmonary tissues, chest radiographic ...
Detection and severity classification of COVID-19 in CT images using deep learning
(
MDPI
, 2021 , Article)
Detecting COVID-19 at an early stage is essential to reduce the mortality risk of the patients. In this study, a cascaded system is proposed to segment the lung, detect, localize, and quantify COVID-19 infections from ...
Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients
(
John Wiley and Sons Inc
, 2021 , Article)
Introduction
Acetylcholinesterase inhibitors (AChEIs) are commonly used to treat mild to moderate cases of Alzheimer disease (AD). To the best of our knowledge, there has been no study estimating the risk of bleeding and ...